VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VIONQ) announced that it had received a response from the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment ("SPA") for its oncology therapeutic Onrigin™ (laromustine) Injection. In January 2010, Vion filed a SPA with the FDA related to a randomized Phase II/III trial of Onrigin™ in combination with low-dose Ara-C (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML)...
More...
More...